.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AF08_Ritlecitinib.Ritlecitinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AF08_Ritlecitinib.Ritlecitinib| name: | Ritlecitinib | |
| ATC code: | L04AF08 | route: | oral |
| compartments: | 2 | |
| dosage: | 50 | mg |
| volume of distribution: | 111 | L |
| clearance: | 12.8 | L/h |
| other parameters in model implementation | ||
Ritlecitinib is an oral, selective kinase inhibitor, primarily targeting Janus kinase 3 (JAK3) and the TEC family of tyrosine kinases. It is approved for the treatment of severe alopecia areata in adults and adolescents.
Pharmacokinetic parameters in healthy adult subjects; typical values after oral administration based on regulatory reports.
Wojciechowski, J, et al., & Nicholas, T (2023). Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development. Clinical pharmacokinetics 62(12) 1765–1779. DOI:10.1007/s40262-023-01318-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37917289